Innovation Think Tank (ITT) organized its annual external Innovation Think Tank exhibition (eITT 2022) on July 28th, 2022 at its headquarters in Erlangen, Germany. The event focused on open innovation, co-creation and disruptive innovations in the area of healthcare.
Best practices and outcomes from ITT global locations at Siemens Healthineers, partner universities, hospitals, Ministry of Health, VC and Start-ups were showcased.
During the last year, we received 11 invitations to set up ITT programs, making a total of 85 ITT activity locations with the aim to address Strategic Business Targets of host institutions and to develop the knowledge economy in the regions.
eITT 2022 included keynote speeches from Elisabeth Staudinger, Dr. Peter Schardt, Bernd Ohnesorge (Siemens Healthineers) and ITT location updates from our esteemed guests and key opinion leaders
- Prof. Dr. Narinder Paul, Chair Department of Medical Imaging, Professor at Western University, Toronto, Ontario, Canada
- Dr. Fatih Mehmet Gul, Vice President - UAE and Growth Office at Fakeeh Care Group, CEO at Fakeeh University Hospital, Dubai, UAE
- Prof. James Moore, Bagrit & RAEng Chair in Medical Device Design at Imperial College London, UK
- Prof. Lino Patricio, Ph.d., MD, Head of Interventional Cardiology, Évora Hospital, Coordinator of the Lifespan chair, Évora University
- Mr. Zaw Ali Khan, Additional Director, Era’s Lucknow Medical College and Hospital, Lucknow, India
- Dr. Talal Al Malki, Chief Executive Officer, Taif Region Healthcare Cluster, Ministry of Health, Kingdom of Saudi Arabia
- Dr. rer. nat. Muhannad Alkassar, Senior physician, Universitätsklinikum Erlangen, Kinderkardiologie/Herzchirurgie
- Dr. Osama Abdullah, MRI Physicist at New York University Abu Dhabi, UAE
- Prof. Ata Akin, Dean of Engineering, Acibadem University, Turkey
- Prof. Michael Friebe, Chief HealthTEC Disruptor / CEO, IDTM GmbH and University Professor, AGH University of Science and Technology
- Ms. Dilek Akgun, Operations Director, ITT UofSc and Research Coordinator and Prof. Neset Hikmet, Director of Applied Sciences - Center for Applied Innovation and Advanced Analytics, University of South Carolina (UofSC), College of Engineering and Computing at UofSC, USA
- Ms. Arzu Fırlarer, Managing Director of Başkent University TTO (Technology Transfer Office)
- Dr. Charles Harr, Chief Medical Officer, WakeMed Health and Hospitals, USA
- Dr. Faisal Hasan, Clinical Division Chief of Cardiology and Associate Professor, Department of Internal Medicine, Division of Cardiology, Rush Medical College, USA
- Mr. Ufuk Eren, CEO, Volitan Global, Turkey
- Dr. Nivisha Parag, Head of Healthcare Management Studies, Regent Business School, Operational director ITT RBS, South Africa
- Prof. Olga Janneth Gomez Ramirez, Directora, Dirección de Investigación y Extensión sede Bogotá (DIEB), Columbia
From an open call for projects, 5 finalists were chosen out of 300+ applications. The top 3 received awards. Congratulations to all the finalists and winners.
The program would not have reached this development without the support of so many leaders and experts, so with the annual "Special Support Award" our team would like to acknowledge your continued contributions for Innovation Think Tank.
Want to know more?
The white papers from various locations (Imperial, ERA, Fakeeh University Hospitals, Acibadem, Evora etc.) and upcoming ITT programs can be visited on our Innovation Think Tank website.
Review eITT 2021
The external Innovation Think Tank Exhibition (eITT) 2021 showcased best practices and outcomes from ITT global locations of Siemens Healthineers and partner universities, hospitals, venture capitalists and start-ups. During the year 2021 alone, ITT has received 12 invitations to set up ITT programs, 10 new ITT activity locations were implemented and over 1000 participants took part in various ITT programs. From an open call for projects, 7 finalists were chosen and the top 3 received awards.
Review eITT 2020
The focus of this year's exhibition was to show the complete pathways for the most prominent diseases (e.g. coronary artery disease, cancer, diabetes etc.), the impact of COVID-19 on them and the possible solutions to solve these challenges. They were in the areas of digitalization, automation, new diagnostic and treatment methods, clinical innovation and process improvements in the healthcare system.
Due to the COVID-19 pandemic and digitalization being one of the key strategies for Siemens Healthineers, we had modified the format of our ITT exhibition 2020 to a virtual recorded event which included
- Recorded speeches from experts and management representatives from Siemens Healthineers and ITT key collaboration partners showing what we did together in the last years, what our plans for the next year are and how interdisciplinary Innovation Think Tank methodology has been helping in addressing the complex challenges in healthcare (bringing experts, disciplines, locations and healthcare system stakeholders together).
- Virtual tour of the ITT Office and lab giving an insight into our infrastructure, methodology and processes.
- Projects in the following areas by ITT Fellows and members from ITT locations and collaborations worldwide
• Facts and figures about 12 diseases, chosen based on top economic burden, social impact and mortality
• How disease pathways get influenced by the challenges from COVID-19
• Possible solutions to address those challenges in various disease pathways
This format allows you to have a look at the speeches of your choice at any time and disease content in the areas of your interest at any time as well as to share feedback with us.
Recorded Speeches from Experts and Management Representatives from Siemens Healthineers and ITT Key Collaboration Partners
Dr. Peter Schardt, Chief Technology Officer, Siemens Healthineers
Dr. Fatih Gül, Chief Operating Officer, Fakeeh University Hospital Dubai
Dr. Sonja Förster, Post Doctoral Researcher, ETH Zurich
Prof. Michael Fisher, Director of Product Development, GCMI
Dr. Charles Harr, Chief Medical Officer – Cardiovascular Thoracic Surgeon, WakeMed Health and Hospital
- Dr. Peter Schardt, Chief Technology Officer, Siemens Healthineers
- Dr. Fatih Gül, Chief Operating Officer, Fakeeh University Hospital Dubai
- Dr. Sonja Förster, Post Doctoral Researcher, ETH Zurich
- Prof. James Moore JR, Bagrit Chair in Medical Device Design, Imperial College London
- Ole Per Måløy, Managing Director Middle East and Southern & Eastern Africa, Siemens Healthineers & Dr. Mohaymen Abdelghany, CEO Al Zahra Hospital
- Prof. Rafael Song, Associate Professor of Mechanical and Biomedical Engineering, New York University Abu Dhabi
- Dr. Osama Abdullah, MRI Physicist, New York University Abu Dhabi
- Andre Heinz, Head of Human Resources, Siemens Healthineers
- Hannah Moon, Global Internship Advisor, Georgia Institute of Technology
- Dr. Kong Jun, General Manager of SSME, Siemens Healthineers
- Renato Buselli, Head of Latin America, Siemens Healthineers
- Prof. Giovanni Cerri, President of the Innovation Board of HCFMUSP
- Prof. Ata Akin, Dean of Engineering, Acibadem University Istanbul
- Sevket On, Managing Director and President, Siemens Healthineers Canada
- Dr. Stefan Henkel, Head of IT, Siemens Healthineers
- Neşet Hikmet, Ph.D., Academic Director & Benjamin Schooley, Ph.D., Innovation Director & Dilek Akgun, RTTP, Operations Director, University of South Carolina ITT Lab
- Prof. Michael Fisher, Director of Product Development, GCMI
- Prof. Andrew Menard, Chief Administrative Officer, Radiology Johns Hopkins
- Dr. Charles Harr, Chief Medical Officer - Cardiovascular Thoracic Surgeon, WakeMed Health and Hospital
- Enis Sonemel, Managing Director of Turkey, Siemens Healthineers
- Prof. Burak Acar, Professor of Electrical and Electronics Engineering & Prof. Suzan Uskudarli, Computer Engineering Department, Boğaziçi University Istanbul
- Ufuk Eren, Chief Executive Officer, Volitan Global
- Prof. David Franklin, Professor for Neuromuscular Diagnostics, Technical University Munich
- Prof. Michael Friebe, HealthTec Innovation Lab, Medical Faculty, Otto-von-Guericke-University Magdeburg
- Steffen März, Chief Financial Officer and Managing Director & Dr. Roopika Menon, Head of Customer Management & Dr. Stefan Foser, Chief Technical Officer, NEO NewOncology
- Prof. Dr. Georg Michelson, Senior Physician, Ophthalmology
- Daniel Rinck, Innovation Manager and Head of Innovation Think Tank at Magnetic Resonance Imaging, Siemens Healthineers
- Prof. Debasish Mishra, School of Bio-Sciences and Technology at Vellore Institute of Technology (VIT)
- Prof. Sandeep Singh, Department of Cardiology, Executive Director, School of International Biodesign, All India Institute of Medical Sciences, New Delhi
- Martin Hecht, Head of PLM at Mechatronic Products, Siemens Healthineers
- Gassan Azem, Head of Computed Tomography Performance Product Line, Siemens Healthineers
Review eITT 2019
Twelve diseases that afflict mankind
It begins with unborn children: how can expectant mothers reduce their child’s risk of disease? How can we improve the diagnosis, treatment and the handling of breast cancer, for example? The “Innovation Think Tank” (ITT) has for the first time developed complex treatment plans for twelve diseases which pose the biggest risk to mankind. The core idea: technological innovation. Some treatment plans were presented internationally at the annual external ITT Exhibition on July 11, 2019.
One in eight women will develop breast cancer in their lifetime. According to the WHO, it is estimated that 627,000 women died from breast cancer in 2018 – that is approximately 15% of all cancer deaths among women. For the patients themselves and their social circle the disease is tragic and traumatic, much the same as many other sometimes fatal diseases. “We want to change that. That's why at ITT we’re analyzing the most difficult points in the treatment paths of the deadliest and most costly diseases over the entire life and disease cycle of humans. This begins in the womb and ends with aftercare,” explains Sultan Haider, founder and head of ITT at Healthineers at this year's Innovation Think Tank exhibition (eITT 2019) in Erlangen.
Basis for joint research and development
He addressed the 130 participants from around 40 international organizations: “We are aware of the problems with the prevention, diagnosis, treatment and aftercare of diseases like breast cancer. Action must be taken, and that’s exactly what we are doing: our response is technological innovations which will help patients, doctors and others involved to prevent the disease or to halt its progress. The technology is available! The important thing now is that all of us - technology companies and start-ups, research institutes and universities - work together to make it operational.” The health system is also groaning under the weight of the worst diseases, says Haider, so much of it is also about reducing the financial burden along the whole treatment pathway. Again, new technologies are the key here.
How do technological innovations help?
They are designed to save time, and therefore money, improve the patient experience and enable access to important information for the doctors, hospital administration or governmental bodies. Specifically, it is about three fields of technology: digital technologies, such as the Internet of Medical Things (IoMT), the 5G mobile communication standard, artificial intelligence or Blockchain which we are combining in the treatment pathways with automated solutions – focusing here on robotics and sensors – and clinical innovations such as new diagnostic methods, digital pathology or minimally invasive procedures for example.
Which diseases are being looked at?
Haider’s ITT team have identified twelve diseases whose global burden – both social and economic – is particularly high:
1. Lung Cancer; 2. Breast Cancer; 3. Leukemia; 4. Chronic Obstructive Pulmonary Disease (COPD); 5. Tuberculosis (TB); 6. Multiple Sclerosis (MS); 7. Alzheimer’s Disease; 8. Parkinson’s Disease; 9. Coronary Artery Disease; 10. Stroke; 11. Diabetes; 12. Traumatic Injuries
Around 150 employees in different ITT teams around the world have already been working for several years to build an enormous and broad database of these diseases. The data comes from, among sources, health organizations and scientific journals. In order to develop the matrix-like, highly complex treatment pathways they followed the life and the progression of the patient with all the different interfaces to their social and medical environment.
“And we’re not just focusing on the time when medical care would usually start, but going back to the very beginning, before somebody who may later become a patient has even been born. Because this is where we lay the foundation for our health.”
What does a treatment pathway look like?
Working prototype of a portable ultrasound device for remote diagnosis.
Each treatment pathway includes predefined stations through which the patient moves. In the case of breast cancer, for example, these are: prenatal, prevention, symptoms, diagnosis, rehabilitation and outpatient care, which includes reintegration into everyday life after inpatient cancer treatment.
“We carefully defined each individual station, from the risk factors for a fetus, through screening and other prevention measures to monitoring progress and the most difficult points.”
- The situation: A patient can sense changes in her breast.
- Points of difficulty: She does not go to a regular check, perhaps because she is worried about the somewhat uncomfortable situation during the examination or the examination itself.
- Possible solutions: An app (digital innovation) reminds her to get her breasts examined. She receives a portable ultrasound device (clinical innovation) for remote diagnosis, which instructs the patient on how to screen her breast herself at home. In addition, if the woman has difficulty detecting changes in her breast an intelligent sensor-equipped bra (digital innovation) could also help her.
The audience are appreciative of ITT's extensive analysis and treatment pathways. Peter Schardt, Chief Technology Officer and responsible for the Technology & Innovation (TI) organization, to which ITT also belongs, is impressed:
“The treatment pathways provide the unique basis for a comprehensive collaboration that will benefit all of us and the patient. As a technology supplier, for example, we can gain valuable information through a mutual, open exchange in order to adapt our products and solutions to the requirements of our customers.”
"Through its global infrastructure, deep data analytics, workshops and ultimately events like the one today, the ITT creates an innovation-friendly environment and a sheer inexhaustible knowledge pool that we should all use. Thanks very much to the ITT team!”
“With jointly defined goals, we can succeed in showing the 'big picture' of a disease, in which experts with very different skillsets can participate. It's great to work with such a dedicated and global team to figure out the key challenges and work together to find a solution.”
Image Gallery - Impressions from the eITT Exhibition 2019